Sandu Pharmaceuticals Ltd.
BSE: SANDUPHQ · Pharmaceuticals
Limited coverage
We are not actively covering this company or have limited coverage today. Click to request coverage.
Snapshot
Unlock Sandu Pharmaceuticals Ltd.'s vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Sandu Pharmaceuticals Limited is an established Indian company specialising in the manufacturing and marketing of Ayurvedic and herbal formulations. The company leverages over a century of heritage to provide traditional medicine solutions across therapeutic segments including digestive health, respiratory care, and women's wellness.
Business Model
The company generates revenue through the production and distribution of proprietary and classical Ayurvedic medicines. It operates manufacturing facilities in Goa and maintains a wide distribution network to serve domestic demand for natural healthcare products.
Management Commentary
Management focuses on integrating traditional Ayurvedic wisdom with modern manufacturing standards to maintain product quality and efficacy. The company continues to prioritise its legacy brand positioning within the Indian natural healthcare market.
Growth Outlook
Growth is driven by the increasing domestic demand for natural and herbal healthcare solutions in India. The company aims to capitalise on its established brand reputation and wide distribution reach to expand its market presence.
Key Risks
- Regulatory Risk. Changes in government regulations regarding the manufacturing and labelling of Ayurvedic medicines could impact operational costs and compliance requirements.
- Supply Chain Volatility. The company is susceptible to fluctuations in the availability and pricing of raw herbal ingredients, which are essential for production.
- Market Competition. Increased competition from both traditional Ayurvedic players and modern FMCG companies entering the natural healthcare space may pressure market share.
- Consumer Preference Shifts. The business relies on sustained consumer trust in traditional medicine, which may be affected by evolving health trends or clinical validation requirements.
Start your research today
Unlock AI insights, financials, peers and live data on Sandu Pharmaceuticals Ltd. and 5,000+ companies — free.
Key Metrics
REVENUE
₹70 Cr
TTM · standalone
NET PROFIT
₹2 Cr
TTM · standalone
EPS
₹1.82
TTM · standalone
RETURN ON EQUITY
4.1%
TTM · standalone
P/E
21.8x
Q4 FY26 · standalone
EV/EBITDA
8.3x
Q4 FY26 · standalone
EBITDA MARGIN
4.9%
TTM · standalone
NET PROFIT MARGIN
0.2%
Q4 FY26 · standalone
DEBT TO EQUITY
0.0x
Q4 FY26 · standalone
Peers · Pharmaceuticals
| Company | Mkt Cap | P/E | EV/EBITDA | Rev Gr YoY | EBITDA Mgn | ROE | ROCE | 1Y Return |
|---|---|---|---|---|---|---|---|---|
Sandu Pharmaceuticals Ltd.SANDUPHQ | ₹37 Cr | 20.99 | 9.10 | 4.1% | 4.9% | 4.1% | 6.3% | -22.0% |
Albert DavidALBERTDAVD | ₹513 Cr | 22.73 | 13.48 | 11.4% | 11.0% | 5.8% | 7.5% | +12.1% |
Jenburkt Pharmaceuticals LimitedJENBURPH | ₹463 Cr | 13.31 | 8.46 | — | 32.0% | 17.6% | 23.2% | -4.3% |
Haleos Labs LimitedHALEOSLABS | ₹452 Cr | 28.60 | 12.72 | -3.1% | 13.6% | 7.4% | 10.3% | — |
TranschemTRANSCHEM | ₹424 Cr | 98.76 | 68.07 | -100.0% | 177.7% | 5.3% | 7.0% | +592.6% |
Medicamen BiotecMEDICAMEQ | ₹338 Cr | 33.59 | 15.53 | 24.7% | 11.3% | 4.1% | 6.2% | -27.9% |
As of Q4 FY26
Financials
Sandu Pharmaceuticals Ltd.
BSE: SANDUPHQ · Pharmaceuticals
Limited coverage
We are not actively covering this company or have limited coverage today. Click to request coverage.
Snapshot
Unlock Sandu Pharmaceuticals Ltd.'s vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Sandu Pharmaceuticals Limited is an established Indian company specialising in the manufacturing and marketing of Ayurvedic and herbal formulations. The company leverages over a century of heritage to provide traditional medicine solutions across therapeutic segments including digestive health, respiratory care, and women's wellness.
Business Model
The company generates revenue through the production and distribution of proprietary and classical Ayurvedic medicines. It operates manufacturing facilities in Goa and maintains a wide distribution network to serve domestic demand for natural healthcare products.
Management Commentary
Management focuses on integrating traditional Ayurvedic wisdom with modern manufacturing standards to maintain product quality and efficacy. The company continues to prioritise its legacy brand positioning within the Indian natural healthcare market.
Growth Outlook
Growth is driven by the increasing domestic demand for natural and herbal healthcare solutions in India. The company aims to capitalise on its established brand reputation and wide distribution reach to expand its market presence.
Key Risks
- Regulatory Risk. Changes in government regulations regarding the manufacturing and labelling of Ayurvedic medicines could impact operational costs and compliance requirements.
- Supply Chain Volatility. The company is susceptible to fluctuations in the availability and pricing of raw herbal ingredients, which are essential for production.
- Market Competition. Increased competition from both traditional Ayurvedic players and modern FMCG companies entering the natural healthcare space may pressure market share.
- Consumer Preference Shifts. The business relies on sustained consumer trust in traditional medicine, which may be affected by evolving health trends or clinical validation requirements.
Start your research today
Unlock AI insights, financials, peers and live data on Sandu Pharmaceuticals Ltd. and 5,000+ companies — free.
Key Metrics
REVENUE
₹70 Cr
TTM · standalone
NET PROFIT
₹2 Cr
TTM · standalone
EPS
₹1.82
TTM · standalone
RETURN ON EQUITY
4.1%
TTM · standalone
P/E
21.8x
Q4 FY26 · standalone
EV/EBITDA
8.3x
Q4 FY26 · standalone
EBITDA MARGIN
4.9%
TTM · standalone
NET PROFIT MARGIN
0.2%
Q4 FY26 · standalone
DEBT TO EQUITY
0.0x
Q4 FY26 · standalone
Peers · Pharmaceuticals
As of Q4 FY26